If a patient with acute kidney injury is receiving ACE inhibitors, the nurse should cautiously monitor for?

HSSC Staff Nurse - 2015

Pharmacology

Hard

Appeared in: HSSC Staff Nurse - 2015

Explanation

ACE inhibitors block the Renin-Angiotensin-Aldosterone System (RAAS), which reduces the production of aldosterone.
Aldosterone is a hormone responsible for promoting potassium excretion in the kidneys.
Reduced aldosterone levels cause the body to retain potassium, leading to hyperkalemia.
Acute Kidney Injury (AKI) already impairs the kidney's ability to filter and excrete potassium.
The combination of AKI and an ACE inhibitor creates a synergistic and dangerous risk for severe hyperkalemia.

Option B: While serum phosphate levels are often elevated in AKI due to decreased renal excretion, ACE inhibitors do not have a direct effect on phosphate metabolism. Therefore, it is not the primary electrolyte to monitor specifically related to ACE inhibitor use.
Option C: Similar to phosphate, serum magnesium can become elevated in patients with severe kidney injury because the kidneys are the primary route of magnesium excretion. However, ACE inhibitors do not directly cause an increase in magnesium levels.
Option D: Serum copper levels are not routinely affected by either acute kidney injury or ACE inhibitor therapy. Monitoring copper is not relevant in this clinical context.

Clinical Relevance

Nursing practice connection: Use the key finding related to Adverse effects of ACE inhibitors in renal impairment to guide bedside assessment, documentation, and the next nursing action.
Hyperkalemia is a medical emergency that can cause fatal cardiac arrhythmias. Nurses must be vigilant in monitoring potassium levels in at-risk patients.
This scenario highlights the critical importance of reviewing a patient's comorbidities (like AKI) before administering medications (like ACE inhibitors) that affect electrolyte balance.
What if the patient was also prescribed a potassium-sparing diuretic like spironolactone? The risk of life-threatening hyperkalemia would be extremely high. This combination is generally contraindicated and requires intense monitoring if used at all.

How to Approach the Question

First, identify the key elements in the question: a patient with 'acute kidney injury' (AKI) is taking an 'ACE inhibitor'.
Recall the pathophysiology of AKI. The primary problem is the kidney's reduced ability to filter waste products and regulate electrolytes.
Next, recall the mechanism of action of ACE inhibitors. They block the RAAS pathway, which specifically leads to decreased aldosterone.
Connect the drug's effect to the patient's condition. Aldosterone's job is to excrete potassium. An ACE inhibitor reduces aldosterone, causing potassium retention.
Synthesize the information: The kidney is already failing to excrete potassium due to AKI, and the drug is adding to the problem by further reducing potassium excretion. This creates a high risk for hyperkalemia.
Evaluate the options. Serum potassium is directly affected by this drug-disease interaction, making it the most critical parameter to monitor.

Concept Tested & Keywords

Concept Tested: Adverse effects of ACE inhibitors in renal impairment
Stem keywords: acute kidney injury, ACE inhibitors, monitor
Lead-in keywords: cautiously monitor for
Clinical cues: Patient has two conditions that both increase potassium: AKI and use of an ACE inhibitor.

QeR0nZh6VjwarZoS6_WNfl

E6 Nelson Textbook of Pediatrics(2024) — Volume 2 p. 1048-1050

E6 Nursing Brunner Adult Health 3SA Vol 1 Part 1 p. 158-159